Crinetics Pharmaceuticals, Inc.
CRNXNASDAQHealthcare● Active
$33.46
+$0.54(+1.64%)
Market Cap$3.5B
P/E Ratio—
52W High$57.99
52W Low$25.83
Crinetics Pharmaceuticals, Inc. (CRNX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CRNX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$1.23
Est. -$1.22 · -0.8%
Revenue
$0.01B
Est. $0.01B · +26.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat Revenue
CRNX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$1.23 | — | — | — | $0.01B | — |
| — Q2 FY2026 | May 7, 2026 | -$1.22 | -$1.23 | -0.8% | $0.01B | $0.01B | +26.1% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$1.37 | -$1.29 | +5.8% | $0.01B | $0.00B | +37.2% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$1.27 | -$1.38 | -8.7% | $0.00B | $0.00B | -96.7% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$1.13 | -$1.23 | -8.8% | $0.00B | $0.00B | +161.7% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.99 | -$1.04 | -5.0% | $0.00B | $0.00B | +3.8% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.92 | -$0.88 | +4.3% | — | $0.00B | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.91 | -$0.96 | -5.4% | — | $0.00B | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$1.23
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026
EPS Actual
-$1.23
EPS Est.
-$1.22
EPS Surpr.
-0.8%
Revenue
$0.01B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$1.29
EPS Est.
-$1.37
EPS Surpr.
+5.8%
Revenue
$0.01B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$1.38
EPS Est.
-$1.27
EPS Surpr.
-8.7%
Revenue
$0.00B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$1.23
EPS Est.
-$1.13
EPS Surpr.
-8.8%
Revenue
$0.00B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$1.04
EPS Est.
-$0.99
EPS Surpr.
-5.0%
Revenue
$0.00B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.88
EPS Est.
-$0.92
EPS Surpr.
+4.3%
Revenue
—
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.96
EPS Est.
-$0.91
EPS Surpr.
-5.4%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.10 | $-0.96 | $-0.76 | 6 |
| Q3 FY2027 | $-1.18 | $-1.02 | $-0.81 | 3 |
| Q2 FY2027 | $-1.22 | $-1.06 | $-0.84 | 5 |
| Q1 FY2027 | $-1.28 | $-1.11 | $-0.88 | 3 |
| Q4 FY2026 | $-1.37 | $-1.18 | $-0.94 | 6 |
| Q3 FY2026 | $-1.34 | $-1.21 | $-0.95 | 8 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.1B | $0.1B | 7 |
| Q3 FY2027 | $0.0B | $0.0B | $0.1B | 4 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 4 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 7 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | -0.8% | $41.71 | $43.49 | +4.27% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +5.8% | $43.39 | $43.74 | +0.81% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -8.7% | $42.53 | $43.49 | +2.26% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -8.8% | $28.53 | $27.88 | -2.28% |
| ▼ Q2 FY2025 | May 8, 2025 | -5.0% | $31.39 | $32.70 | +4.17% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +4.3% | $32.55 | $33.21 | +2.03% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -5.4% | $60.01 | $58.78 | -2.05% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -9.3% | $48.30 | $50.74 | +5.05% |
Q2 FY2026+4.27%
Report Date
May 7, 2026
EPS Beat/Miss
-0.8%
Price Before
$41.71
Price After
$43.49
Q1 FY2026+0.81%
Report Date
Feb 26, 2026
EPS Beat/Miss
+5.8%
Price Before
$43.39
Price After
$43.74
Q4 FY2025+2.26%
Report Date
Nov 6, 2025
EPS Beat/Miss
-8.7%
Price Before
$42.53
Price After
$43.49
Q3 FY2025-2.28%
Report Date
Aug 7, 2025
EPS Beat/Miss
-8.8%
Price Before
$28.53
Price After
$27.88
Q2 FY2025+4.17%
Report Date
May 8, 2025
EPS Beat/Miss
-5.0%
Price Before
$31.39
Price After
$32.70
Q1 FY2025+2.03%
Report Date
Feb 27, 2025
EPS Beat/Miss
+4.3%
Price Before
$32.55
Price After
$33.21
Q4 FY2024-2.05%
Report Date
Nov 12, 2024
EPS Beat/Miss
-5.4%
Price Before
$60.01
Price After
$58.78
Q3 FY2024+5.05%
Report Date
Aug 8, 2024
EPS Beat/Miss
-9.3%
Price Before
$48.30
Price After
$50.74
Avg Beat Reaction+2.37%
Avg Miss Reaction+1.43%
Beat Rate3 / 8 quarters
Largest Move+5.05% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CRNX ends December
Crinetics Pharmaceuticals, Inc. (CRNX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-1.23 (in line with the analyst consensus of $-1.22). The next CRNX earnings date is expected around September 1, 2026.
Each quarter, investors track CRNX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CRNX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CRNX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CRNX earnings · 4 questionsCrinetics Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. CRNX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CRNX historically reports after market close (AMC).
CRNX earnings datewhen is CRNX earningsCRNX next earnings datewhen does CRNX report earningsCRNX earnings calendar
▸ Source: FMP · Crinetics Pharmaceuticals, Inc. SEC filings · US GAAP · Crinetics Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026